{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:55:56Z","timestamp":1770137756325,"version":"3.49.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Objective<\/jats:title>\n To investigate the efficacy and safety of pemetrexed\/platinum-based chemotherapy combined with or without bevacizumab after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of patients with malignant peritoneal mesothelioma (MPM).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A retrospective non-randomized study was performed on 205 MPM patients treated with CRS+HIPEC at our institution. A total of 97 eligible patients were analyzed: 58 patients who received postoperative chemotherapy combined with bevacizumab (C&amp;B) and 39 patients who received chemotherapy alone (C) were divided into a study group and a control group, respectively. The patients were also divided into the bevacizumab-exposed subgroup and the bevacizumab-unexposed subgroup based on whether they had a history of bevacizumab infusion. Clinicopathological data and follow-up information were statistically analyzed. Independent prognostic factors were identified via survival analysis, and the safety of combination therapy was assessed via adverse event analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n As of the follow-up cutoff date of July 1, 2025, in both the subgroups with and without a history of bevacizumab infusion, there was no statistically significant difference between the control and study groups in baseline pathological characteristic parameters (\n p<\/jats:italic>\n &gt; 0.05). Survival analysis revealed that in the subgroup of patients with a history of bevacizumab infusion, the difference in median overall survival (mOS) between the control and study groups was statistically significant (31.9 months\n vs.<\/jats:italic>\n NR;\n p<\/jats:italic>\n = 0.031), and the difference in median disease-free survival (mDFS) between the control and study groups was statistically significant (12.5 months\n vs<\/jats:italic>\n . NR;\n p<\/jats:italic>\n = 0.001); in the subgroup of patients without a history of bevacizumab infusion, the difference in mOS between the control and study groups was also statistically significant (20.5 months\n vs.<\/jats:italic>\n NR;\n p<\/jats:italic>\n = 0.001), and the difference in mDFS between the control and study groups was statistically significant (13.2\n vs<\/jats:italic>\n . 36.2 months;\n p<\/jats:italic>\n = 0.001). The Cox regression model found that postoperative C&amp;B was an independent prognostic factor (\n p<\/jats:italic>\n = 0.009, HR = 0.081, 95% CI: 0.012\u20130.526) in the subgroup with a history of bevacizumab infusion, and the Ki-67 index (\n p<\/jats:italic>\n = 0.043, HR = 2.563, 95% CI: 1.029\u20136.386) and postoperative C&amp;B were independent prognostic factors (\n p<\/jats:italic>\n = 0.01, HR = 0.086, 95% CI: 0.032\u20130.232) in the subgroup with no bevacizumab treatment history. A total of 101 cases of grade 1~2 adverse events in the study group were revealed via adverse event analysis, with common events including nausea\/vomiting, fatigue, leukopenia\/neutropenia, thrombocytopenia, anemia, abnormal liver function, hypertension, and proteinuria. There were four cases with grade 3 adverse events, mainly leukopenia\/neutropenia, hypertension, and proteinuria. In the control group, there were 84 cases of grade 1~2 adverse events, and three cases of grade 3 adverse events were observed.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Our exploratory findings suggest that bevacizumab combined with pemetrexed\/platinum-based chemotherapy may be a therapeutic option for MPM patients after CRS+HIPEC; however, a prospective, randomized controlled clinical study is needed to validate our findings.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2026.1733967","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:21:44Z","timestamp":1770096104000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhi-Ran","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Li","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Bao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He-Liang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Dong","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Beijing Tsinghua Changgung Hospital, Tsinghua University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-Lin","family":"An","sequence":"additional","affiliation":[{"name":"Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.12.15","article-title":"Peritoneal mesothelioma","volume":"9","author":"Greenbaum","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2022.2066728","article-title":"Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse Malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China","volume":"39","author":"Su","year":"2022","journal-title":"Int J Hyperthermia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5278.146897","article-title":"Global mesothelioma epidemic: trend and features","volume":"18","author":"Bianchi","year":"2014","journal-title":"Indian J Occup Environ Med"},{"key":"B4","first-page":"32","article-title":"Peritoneal mesothelioma: a review","volume":"9","author":"Bridda","year":"2007","journal-title":"MedGenMed"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2011.10.006","article-title":"Diffuse Malignant peritoneal mesothelioma-an update on treatment","volume":"38","author":"Mirarabshahii","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2010-0550-RS","article-title":"Malignant mesothelioma of the tunica vaginalis testis: diagnostic studies and differential diagnosis","volume":"136","author":"Chekol","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3390\/cancers14040942","article-title":"Incidence, survival analysis and future perspective of primary peritoneal mesothelioma (PPM): A Population-Based Study from SEER Database","volume":"14","author":"Ullah","year":"2022","journal-title":"Cancers"},{"key":"B8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3390\/cancers15030662","article-title":"Diagnostic and therapeutic pathway in diffuse Malignant peritoneal mesothelioma","volume":"15","author":"Kusamura","year":"2023","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-009-9328-9","article-title":"Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005","volume":"20","author":"Moolgavkar","year":"2009","journal-title":"Cancer Causes Control"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0b013e3282f0c0a2","article-title":"US mesothelioma patterns 1973-2002: indicators of change and insights into background rates","volume":"17","author":"Teta","year":"2008","journal-title":"Eur J Cancer Prev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl345","article-title":"Epidemiology of peritoneal mesothelioma: a review","volume":"18","author":"Boffetta","year":"2007","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with Malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","article-title":"Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"47","author":"Kusamura","year":"2021","journal-title":"Eur J Surg Oncol Eur J Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10552-009-9328-9","article-title":"Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008","volume":"19","author":"Henley","year":"2013","journal-title":"Int J Occup Environ Health"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1 associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a rand omised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000543889","article-title":"Successful response to first-line carboplatin, pemetrexed, and bevacizumab for peritoneal mesothelioma: two case reports","volume":"18","author":"Tomonobu","year":"2025","journal-title":"Case Rep Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2013.01.001","article-title":"Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with Malignant peritoneal mesothelioma","volume":"153","author":"Alexander Jr","year":"2013","journal-title":"Surgery"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.05.027","article-title":"Diffuse Malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"49","author":"Baratti","year":"2013","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-5834-2","article-title":"Preoperative thrombocytosis predicts shortened survival in patients with Malignant peritoneal mesothelioma undergoing operative cytoreduction and hyperthermic intraperitoneal chemotherapy","volume":"24","author":"Li","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3182a0e867","article-title":"Prognostic significance of Ki67 expression in Malignant peritoneal mesothelioma","volume":"38","author":"Pillai","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000181","article-title":"Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients","volume":"46","author":"Liu","year":"2014","journal-title":"Pathology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1884","article-title":"P16 loss and mitotic activity predict poor survival in patients with peritoneal Malignant mesothelioma","volume":"11","author":"Borczuk","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2223374","DOI":"10.1080\/02656736.2023.2223374","article-title":"Establishment of a Bayesian network model to predict the survival of Malignant peritoneal mesothelioma patients after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy","volume":"40","author":"Su","year":"2023","journal-title":"Int J Hyperthermia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70128","article-title":"Efficacy of postoperative immunotherapy on MPM patients after CRS+HIPEC: A single-center retrospective study based on propensity score matching","volume":"158","author":"Liang","year":"2026","journal-title":"Int J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1733967\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:21:45Z","timestamp":1770096105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1733967\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":25,"alternative-id":["10.3389\/fonc.2026.1733967"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1733967","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"article-number":"1733967"}}